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Abstract
Background
Transforming growth factor beta (TGF-β) signalling is involved in the development of hepa-
tocellular carcinoma (HCC). We followed changes in biomarkers during treatment of
patients with HCC with the TGF-βRI/ALK5 inhibitor galunisertib.
Methods
This phase 2 study (NCT01246986) enrolled second-line patients with advanced HCC into
one of two cohorts of baseline serum alpha-fetoprotein (AFP): Part A (AFP�1.5x ULN) or
Part B (AFP <1.5x ULN). Baseline and postbaseline levels of AFP, TGF-β1, E-cadherin,
selected miRNAs, and other plasma proteins were monitored.
Results
The study enrolled 149 patients (Part A, 109; Part B, 40). Median OS was 7.3 months in Part
A and 16.8 months in Part B. Baseline AFP, TGF-β1, E-cadherin, and an additional 16
plasma proteins (such as M-CSF, IL-6, ErbB3, ANG-2, neuropilin-1, MIP-3 alpha, KIM-1,
uPA, IL-8, TIMP-1, ICAM-1, Apo A-1, CA-125, osteopontin, tetranectin, and IGFBP-1) were
found to correlate with OS. In addition, a range of miRs were found to be associated with
OS. In AFP responders (21% of patients in Part A with decrease of >20% from baseline) ver-
sus non-responders, median OS was 21.5 months versus 6.8 months (p = 0.0015). In TGF-
β1 responders (51% of all patients) versus non-responders, median OS was 11.2 months
versus 5.3 months (p = 0.0036).
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Conclusions
Consistent with previous findings, both baseline levels and changes from baseline of circu-
lating AFP and TGF-β1 function as prognostic indicators of survival. Future trials are needed
to confirm and extend these results.
Introduction
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and is increas-
ing in incidence [1]. Systemic treatment options are currently limited to a few agents, such as
sorafenib, regorafenib, cabozantinib, or immuno-oncology drugs [2–4]. With an increased
understanding of the underlying disease process in HCC, novel treatments are being devel-
oped that target specific pathways associated with disease progression [5].
The transforming growth factor beta (TGF-β) signalling pathway was identified as being
active in a specific subclass of HCC [6]. However, high circulating levels of TGF-β1 in patients
suggest that this pathway may be more broadly active in HCC [7, 8]. In preclinical studies,
TGF-β signalling was found to modulate E-cadherin, vimentin, and integrin expression in
HCC cells, implying a role in triggering the epithelial-mesenchymal transition (EMT) [9–13].
The small molecule galunisertib, a selective inhibitor of the serine/threonine kinase of the
TGF-β receptor type I (TGF-β RI) [14], reversed E-cadherin secretion in highly invasive HCC
cell lines and increased the expression of E-cadherin on tumor cells [13]. This change was asso-
ciated with a reduction in invasion and metastasis [9, 13].
We investigated the activity of galunisertib in two groups of patients with HCC separated
by baseline serum alpha fetoprotein (AFP) levels: elevated, or normal to very low. We moni-
tored changes in serum AFP and in plasma TGF-β1 and E-cadherin during treatment. We also
assessed other circulating biomarkers, including selected microRNA (miRNA). Where avail-
able, we stained tumor tissue samples of patients to determine tumor expression of E-cadherin.
All markers were tested for association with overall survival (OS) to determine their potential
for prognostic or predictive use in future randomized clinical trials.
Methods
Ethics approval
Each institution’s review board approved the study and all patients signed an informed con-
sent document before study participation. The complete list of ethics committee names and
reference numbers is in S2 Table. The study was conducted according to the principles of
good clinical practice, applicable laws and regulations, and the Declaration of Helsinki.
Patients and study design
This was an open-label, multicentre, two-part phase 2 study in patients aged 18 years or older
with histological evidence of HCC (not amenable to curative surgery), Child-Pugh Class A or
B7, measurable disease (RECIST 1.1), Eastern Cooperative Oncology Group Performance Sta-
tus�1, and who had received sorafenib and had progressed or were ineligible for sorafenib
treatment. Part A included patients with baseline serum AFP�1.5x upper limit of normal
(ULN); these patients were randomly assigned to two cohorts based on initial dose of galuni-
sertib (80 or 150 mg BID) [15]. Part B enrolled patients with AFP<1.5x ULN to receive galuni-
sertib at 150 mg BID. In both parts, galunisertib was given for 14 days followed by 14 days of
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rest per 28-day cycle. The primary objective was to characterise time-to-tumor progression
(TTP) and the effect of treatment on TGF-β-associated plasma biomarkers (TGF-β1, AFP and
E-cadherin). The study is registered at ClinicalTrials.gov as NCT01246986.
Biomarker methods
Plasma or serum samples were analysed for TGF-β1 or AFP levels by ELISA (R&D Systems,
DB100B, Minneapolis, Minnesota, USA or Quintiles, Durham, North Carolina, USA, respec-
tively). Except for the initial assessment of serum AFP at the institutional laboratory for the
purpose of assignment to Part A or Part B, all baseline and treatment measurements were
done at a central laboratory (Quintiles, Durham, North Carolina, USA). The Multianalyte
Immunoassay Panel (MAP), using bead array technology developed by Myriad RBM, con-
sisted of approximately 245 plasma proteins; E-cadherin was measured separately (Myriad
RBM, Salt Lake City, Utah, USA).
Selected miRNAs in plasma (total 752) were measured using the Exiqon RT microRNA
PCR Human panel I+II (Qiagen Inc., Germantown, Maryland, USA). Covance Genomics Lab-
oratories (Seattle, Washington, USA) performed the miR extraction and detection assays.
Tumor tissue, when available, was tested for expression of the following 11 proteins by
immunohistochemistry (IHC): cMET, E-cadherin, Glypican-3, PIVKAII, pSMAD2, TGFBR2,
AFP, CASPASE3, CD8, CK19 and Ki67 (AAREC Filia Research, Paris, France).
A complete differential blood count was done for lymphocytes, neutrophils and monocytes
at a central laboratory (Quintiles, Durham, NC, USA). In a subgroup of patients from Part B,
T cell subsets, including CD3+, CD4+, and CD8+, were also evaluated.
Statistical analyses
AFP, TGF-β1 and E-cadherin levels were measured at baseline and at every 2 weeks after treat-
ment start. When this study was designed, TTP was the recommended endpoint for HCC
studies [16]. However, emerging preclinical data indicated that galunisertib treatment reverted
EMT [13]. which suggested that evaluable responses and clinical benefit may be delayed, even
after treatment discontinuation. Hence, all biomarker responses were assessed using OS and
not TTP.
To evaluate if each parameter was prognostic for OS, all patients from both parts were split
into two groups, cut at the median of the baseline values of TGF-β1 and E-cadherin and at 400
ng/ml for AFP. Patients were included in the analysis of response if they had at least one evalu-
able measure at baseline and at any time post-treatment initiation. Patients were considered
responders if they achieved >20% decrease from baseline at any visit in the first 6 cycles of
treatment, regardless of how many cycles of treatment they completed [17]. For AFP response,
only patients in Part A were included in the analysis. For AFP responders, the time of the first
occurrence and the subsequent duration of biomarker response was calculated and summa-
rised. For patients who maintained a response at their last assessment, duration was censored
at the last visit on which a sample was taken.
OS was summarised descriptively using the Kaplan-Meier method by baseline and subse-
quent response status of circulating AFP, TGF-β1, and E-cadherin, and used the log-rank test
for comparisons.
The MAP developed by Myriad RBM consisted of approximately 245 plasma markers.
Potential prognostic markers as measured at baseline were evaluated for their impact on OS.
Data were pooled across Parts A and B of the study and patients were split into two groups
based on the median value for each biomarker, >median or�median. Univariate Cox regres-
sion models were used to select markers prognostic for OS with p�0.001. There was no
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adjustment for multiplicity given the exploratory nature of the analyses. Spearman’s rank cor-
relation was also estimated between AFP and each of the prognostic markers to verify if any
findings may be attributed to an underlying correlation. For identified prognostic markers,
changes in the first 6 cycles after treatment with galunisertib were evaluated using mixed effect
model repeated measures (MMRM) models. A landmark analysis at 6 cycles was chosen to
minimize confounding by multiple measurements in patients on the study longer. Data were
loge-transformed prior to analysis and the ratio to baseline evaluated, with baseline as a covari-
ate, and fixed effect terms of study part, visit, and the interaction of study part and visit. An AR
(1) variance-covariance structure was used to account for repeated measures within a patient.
Lymphocytes, neutrophils and monocytes were evaluated at baseline, weekly during cycle 1,
and biweekly during cycle 2 onwards in Parts A and B. T-cell subsets including CD4+, CD8
+ and CD3+ were not available for all patients, and were evaluated at baseline for 23/40
patients in Part B. Each laboratory parameter was categorised as low, normal or high at base-
line according to central laboratory-defined normal ranges. OS and changes from baseline
over the first 6 cycles were summarised and compared using similar methods as for other
biomarkers.
For each miRNA, patients were split into four groups by baseline values, using first quartile,
median and third quartile as cut-offs. Cox regression was performed using OS as response var-
iable and grouped biomarker as explanatory variable. The statistical significance of the result-
ing hazard ratios (HRs) were assessed using the likelihood ratio test. The p values were
adjusted by Bonferroni correction within each biomarker and then the adjusted p values were
again adjusted globally via the false discovery rate method. Median OS and confidence inter-
vals were calculated using the Kaplan-Meier method. For IHC data, similar analyses were per-
formed based on dichotomisation of median for each biomarker.
Results
Patients
Patients (n = 149) were enrolled between April 19, 2011 and April 3, 2013, and the cut-off date
for the data in this report was May 15, 2015. Of 149 patients who received at least one dose of
study drug, 127 (85.2%) were men and 127 (85.2%) were white. Mean age was 64.6 years
(range: 31–89 years) and mean weight was 75.4 kg (range: 40.0–120.4 kg) (S1 Table) [15]. In
Part A (n = 109), 37 received galunisertib at 80 mg BID, and 72 at 150 mg BID; in Part B, 40
received galunisertib at 150 mg BID. A total of 144 patients discontinued study treatment (Part
A, 108; Part B, 36). Five patients (Part A,1; Part B, 4) were continuing to receive study treat-
ment at the time of the data cut-off. The most common reasons for treatment discontinuation
were progressive disease (98 patients: Part A, 73; Part B, 25), death (20 patients: Part A, 18;
Part B, 2) and adverse event (11 patients: Part A, 7; Part B, 4).
Correlation of biomarkers to survival
The two dose groups of Part A were pooled to enhance the sample size for exploration of bio-
marker subsets. Median OS was 7.3 months (95% CI: 4.9–10.5) in Part A and 16.8 months
(95% CI: 10.5–24.4) in Part B. The log rank p-value for OS for Part A vs Part B was p = 0.001.
Combining Parts A and B, and grouping by baseline AFP (>400 ng/mL,�400 ng/mL),
higher baseline AFP (n = 66) was associated with shorter median OS of 5.6 months (95% CI:
3.4–8.9) compared to 13.0 months (95% CI: 10.5–16.6) for lower baseline AFP (n = 81)
(p = 0.0003) (Table 1, Fig 1A).
Median baseline TGF-β1 was 3.52 ng/mL. For patients with baseline TGF-β1 above the
median (n = 74), median OS was 5.4 months (95% CI: 3.1–10.8) compared to 12.1 months
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(95% CI: 8.9–15.5) for patients with baseline TGF-β1�median (n = 74), p = 0.022 (Table 1,
Fig 1B). The results were similar when the data was examined for Part A and Part B separately,
where in both parts the median OS was approximately 2-fold longer for the group of patients
Table 1. Evaluation of OS by baseline AFP and TGF-β1 (Parts A and B combined).
Baseline biomarker status n Median OS 95% CI p-value1
Baseline AFP
>400 ng/mL 66 5.6 mo 3.4–8.9
�400 ng/mL 81 13.0 mo 10.5–16.6 0.0003
Baseline TGF-β12
>median 74 5.4 mo 3.1–10.8
�median 74 12.1 mo 8.9–15.5 0.022
1p-value for difference between baseline biomarker status groups.
2Median baseline TGF-β1 was 3.52 ng/mL.
AFP = alpha fetoprotein; mo = months; OS = overall survival; TGF-β1 = transforming growth factor beta 1.
https://doi.org/10.1371/journal.pone.0222259.t001
Fig 1. OS by baseline biomarker status (Parts A and B combined). (A) Baseline AFP: low,�400 ng/mL, high,>400 ng/mL. (B) Baseline TGF-β1. (C) Baseline
E-Cadherin. Baseline levels were split at the median for high versus low comparison for TGF-β1 and E-cadherin.
https://doi.org/10.1371/journal.pone.0222259.g001
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whose baseline TGF-β1 was�median value [15]. This observation is supported by the results
from the multivariate Cox regression models combining data across study parts, which pro-
vided evidence that TGF-β1 and AFP were independently prognostic for OS (p<0.1) [15].
Median baseline plasma E-cadherin was 6.21 mg/mL. For the group of patients whose base-
line E-cadherin was above the median value, median OS was 6.3 months (95% CI: 4.2–10.5)
compared to 13.0 months (95% CI: 8.9–15.5) for the group whose baseline E-cadherin
�median (p = 0.047) (Fig 1C).
AFP response was evaluated only for patients from Part A. In Part A, 22 (21%) patients
demonstrated an AFP response, with a median OS of 21.5 months (95% CI: 6.8–25.1) com-
pared to 6.8 months (95% CI: 4.5–8.9) for patients without an AFP response (p = 0.0015)
(Table 2, Fig 2A). Median time to first response was 1.4 months, with a median duration of 1
month; however, 5 patients showed a response lasting more than 4 months.
TGF-β1 response was evaluated for all patients combined. Seventy-eight (55%) patients
achieved a TGF-β1 response, with a median OS of 14.0 months (95% CI: 10.5–16.8) compared
to 5.6 months (95% CI: 3.4–9.0) for patients without a TGF-β1 response (n = 64) (p = 0.0036)
(Table 2, Fig 2B). TGF-β1 responses appeared earlier than AFP responses (median time to
first response, 0.5 months; median duration, 0.6 months). The shorter duration of response
may have been due to the intermittent dosing schedule of galunisertib, with a coinciding fluc-
tuating TGF-β1 response profile (S1 Fig).
Table 2. Evaluation of OS by AFP, TGF-β1 and E-cadherin responses.
Part A N = 109 Part B N = 40 Total N = 149
n (%) Median OS (mo) (95% CI) n (%) Median OS (mo) (95% CI) n (%) Median OS (mo) (95%
CI)
AFP
n (patients with data) 103 AFP changes not evaluated for study Part B.
Responder 22 (21%) 21.5 (6.8, 25.1)
Non-Responder 81 (79%) 6.8 (4.5, 8.9)
p-valuea 0.0015
Duration of Response1 1.0 (0.5-NE)
Time to 1st response2 1.0 (1.0–2.8)
TGF- β1
n (patients with data) 103 39 142
Responder 50 (51%) 11.2 (6.8–14.5) 28 (72%) 21.9 (12.4 –NC) 78 (55%) 14.0 (10.5–16.8)
Non-Responder 53 (49%) 5.3 (3.0–8.9) 11 (28%) 10.5 (1.5–16.5) 64 (45%) 5.6 (3.4, 9.0)
p-valuea 0.1414 0.0233 0.0036
Duration of Response1 0.6 (0.5, 1.4) 0.8 (0.5, 1.0) 0.6 (0.5, 1.0)
Time to 1st response2 0.5 (0.5–1.0) 0.5 (0.5–1.4) 0.5 (0.5–1.4)
E-Cadherin
n (patients with data) 100 39 139
Responder 39 (39%) 8.9 (4.9–15.3) 18 (46%) 24.2 (13.0-NE) 57 (41%) 13.0 (7.9–17.5)
Non-Responder 61 (61%) 8.3 (4.5–11.6) 21 (56%) 10.5 (5.6–21.5) 82 (59%) 8.4 (5.6–11.7)
p-valuea 0.7647 0.0576 0.1331
Duration of Response1 1.0 (0.5, 1.0) 0.9 (0.5, 1.0) 1.0 (0.5, 1.0)
Time to 1st response2 1.0 (0.5–1.4) 1.0 (0.5–1.4) 1.0 (0.5–1.4)
ap-value calculated using the log-rank test for the within study part comparison of the indicated response vs no response comparison
1Median (mo) (95% CI)
2Median (mo) (25th percentile, 75th percentile)
https://doi.org/10.1371/journal.pone.0222259.t002
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For patients who had an E-cadherin response, median OS was numerically, but not statisti-
cally, longer compared to E-cadherin non-responders (13.0 vs 8.4 mo, p = 0.13) (Table 2, Fig 2C).
Of 50 patients in Part A who achieved a TGF-β1 response, 16 achieved an AFP response.
The subset of 16 patients achieving both TGF-β1 and AFP responses had median OS of 21.5
months (95% CI: 12.5–28.1) compared to 7.3 months (4.8–11.7) for patients achieving only
AFP or TGF-β1 response, and 5.6 months (95% CI: 3.0–8.9) for patients with neither TGF-β1
nor AFP response (Fig 2D). These findings suggest that TGF-β1 and AFP may be used as com-
plementary markers for treatment response in future studies.
Finally, we investigated the association between higher TGF-β1 or AFP at baseline, TGF-β1
response, and OS. For patients with higher baseline levels of TGF-β1, 50/68 (73.5%) achieved a
TGF-β1 response with median OS of 10.8 months (95% CI: 5.4–14.5) compared to 2.2 months
(95% CI: 1.5–3.0) for patients without a TGF-β1 response, p<0.0001 (Fig 3A). For patients
with higher baseline AFP, 32/63 (50.8%) achieved TGF-β1 response with median OS of 10.1
months (95% CI: 5.4–18.0), compared to 3.4 months (2.2–5.6) for patients without a TGF-β1
response, p<0.0001 (Fig 3B).
Fig 2. OS by biomarker response status. (A) AFP (Part A only). (B) TGF-β1 (Parts A and B combined). (C) E-cadherin (Parts A and B combined). (D) Overlap of
responders for AFP and TGF-β1 (Part A only). Patients were considered a responder if they had>20% decrease from baseline in that biomarker at any time in the first
six treatment cycles.
https://doi.org/10.1371/journal.pone.0222259.g002
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The number of patients receiving post-discontinuation anticancer therapies was 41 (29%)
and the proportion was similar for patients with or without TGF-β1 response. The most com-
mon post-discontinuation drug used was sorafenib (10%) followed by oxaliplatin (8%);
Fig 3. OS by the combination of baseline AFP and TGF-β1, and TGF-β1 response (Parts A and B patients). (A) Baseline TGF-β1 and
TGF-β1 response. (B) Baseline AFP and TGF- β1 response.
https://doi.org/10.1371/journal.pone.0222259.g003
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proportions were similar in Part A and Part B. On average, time on either agent was no longer
than 1 cycle. Thus, the relationship of TGF-β1 response to OS was unlikely to be impacted by
post-discontinuation therapies.
Multianalyte immunoassay panel
Of the 245 proteins tested, 33 had >50% of samples below the limit of quantification at base-
line and were excluded from analysis, leaving 212 proteins evaluable. Of the 212 proteins, 17
were identified to be prognostic for OS (p<0.001) using the univariate Cox regression model
(Table 3). Tetranectin and apolipoprotein A-I were found to be associated with longer OS
when baseline levels were high (>median). All other parameters were associated with longer
OS when baseline levels were low (�median). Changes in each of the 17 prognostic markers
were evaluated after treatment with galunisertib (Fig 4), with the following findings:
1. AFP, CA-125 and KIM-1 levels increased by approximately 50% or more after treatment
with galunisertib among patients with elevated AFP (�1.5x ULN) at baseline (Part A), but
not in patients with AFP<1.5x ULN at baseline (Part B). Similar effects were also observed
but with smaller magnitude for hGH, IL-6, IL-8, MIP-3α and RTK erbB-3.
2. ANGPT2 and M-CSF1 levels showed small increases after treatment for both study parts,
with increases more prominent in Part A.
3. APOA1 levels showed modest decreases after treatment in both study parts.
4. VEGF-D showed modest decreases after treatment in Part B, with no trends in Part A.
5. There were no consistent increases or decreases after treatment observed in either study
part for ICAM-1, NRP1, tetranectin, TIMP-1 or uPA.
6. Moderate correlation (�0.5) to AFP was observed for VEGF-D. For all other parameters,
correlations were weak.
Table 3. Single biomarker analysis: HR for OS by high vs low baseline value and correlation to AFP.
Marker OS comparison (high vs low)� HR (95% CI) p-value Correlation coefficient to AFP
Macrophage Colony-Stimulating Factor 1 (M-CSF) 2.47 (1.71,3.56) < .0001 0.15
Interleukin-6 (IL-6) 2.37 (1.65,3.42) < .0001 0.41
Receptor tyrosine-protein kinase erbB-3 (ErbB3) 2.21 (1.54,3.18) < .0001 0.23
Angiopoietin-2 (ANG-2) 2.16 (1.50,3.10) < .0001 0.23
Neuropilin-1 2.47 (1.61,3.81) < .0001 0.04
Alpha Fetoprotein (AFP) 2.10 (1.46,3.03) < .0001 1.00
Macrophage Inflammatory Protein-3 alpha (MIP-3 alpha) 2.08 (1.45,2.99) < .0001 0.40
Kidney Injury Molecule-1 (KIM-1) 2.07 (1.44,2.98) < .0001 0.25
Urokinase-type Plasminogen Activator (uPA) 2.07 (1.43,2.99) < .0001 0.41
Interleukin-8 (IL-8) 2.03 (1.41,2.91) < .0001 0.30
Tissue Inhibitor of Metalloproteinases 1 (TIMP-1) 1.93 (1.35,2.77) 0.0003 0.24
Intercellular Adhesion Molecule 1 (ICAM-1) 1.94 (1.35,2.79) 0.0004 0.18
Apolipoprotein A-I (Apo A-I) 0.51 (0.35,0.74) 0.0004 -0.22
Cancer Antigen 125 (CA-125) 1.92 (1.33,2.77) 0.0005 0.04
Osteopontin 1.90 (1.33,2.73) 0.0005 0.18
Tetranectin 0.53 (0.37,0.76) 0.0007 -0.13
Insulin-like Growth Factor-Binding Protein 1 (IGFBP-1) 1.84 (1.28,2.65) 0.0009 0.24
�Marker categorised as high or low at baseline by value above or below the median. Data for Parts A and B combined.
https://doi.org/10.1371/journal.pone.0222259.t003
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T-cell subsets and haematological assessments
Baseline numbers of lymphocytes, neutrophils and monocytes were assessed for all patients.
Median OS was longer in patients with low to normal (vs high) neutrophils and monocytes (S2
Fig). Patients were considered responders if they had a>20% decrease at any time in the first six
treatment cycles. Patients who were able to maintain levels of lymphocytes (no decrease>20%) or
reduce levels of neutrophils or monocytes (decrease>20%) had improved OS, but differences
were not statistically significant (S3 Fig). T-cell subsets including CD4+, CD8+ and CD3+ were
available for 23 of 40 patients in Part B; no significant associations with OS were identified.
microRNA
Selected circulating miRNAs (miRs) were measured for 105 patients from Part A at baseline
and during treatment at cycle 2, day 14 (C2,D14). The correlation of baseline expression of the
measured miRs with OS is shown in Table 4. The top eight prognostic miRs were analysed for
modulation after treatment, and none were modulated at C2,D14.
Tumor tissue IHC
No analysis was performed for proteins AFP, CK19, CASPASE3, Ki67 and CD8 because of
insufficient samples. For AFP, only 10% of samples scored for any detectable signal. cMET, E-
Fig 4. Geometric mean ratio to baseline for selected proteins from the Multianalyte Immunoassay Panel (Parts A and B). Shaded area represents the
confidence band and is color-coded by study part.
https://doi.org/10.1371/journal.pone.0222259.g004
Table 4. Baseline miR expression associated with OS.
microRNA p value Adjusted p value HR Size low count Size high count FDR
hsa-miR-665 0.00124 0.00372 0.498 53 52 0.129
hsa-miR-320d 0.00125 0.00375 0.440 27 78 0.129
hsa-miR-320a 0.00126 0.00377 0.466 79 26 0.129
hsa-miR-1972 0.00150 0.00451 0.500 53 52 0.129
hsa-miR-451a 0.00161 0.00482 1.99 53 52 0.129
hsa-miR-130b-3p 0.00169 0.00507 0.441 27 78 0.129
hsa-let-7g-5p 0.00170 0.00511 2.25 79 26 0.129
hsa-miR-18a-3p 0.00176 0.00527 1.97 51 50 0.129
hsa-miR-339-5p 0.00420 0.0126 0.485 72 24 0.242
hsa-miR-29b-3p 0.00513 0.0154 1.83 54 51 0.273
hsa-miR-210 0.00707 0.0212 0.494 27 78 0.325
hsa-miR-425-5p 0.00978 0.0293 1.91 79 26 0.378
hsa-miR-346 0.0104 0.0312 0.523 26 76 0.387
hsa-miR-320c 0.0113 0.0339 0.531 27 78 0.400
hsa-miR-877-5p 0.0117 0.0351 0.543 77 28 0.406
hsa-miR-30d-5p 0.0118 0.0353 1.86 79 26 0.407
hsa-miR-363-3p 0.0121 0.0362 1.71 53 52 0.411
hsa-miR-337-3p 0.0145 0.0435 0.546 72 23 0.438
hsa-miR-10b-5p 0.0151 0.0453 1.68 53 52 0.443
hsa-let-7g-5p 0.0152 0.0457 1.89 76 25 0.445
FDR = false discovery rate; HR = hazard ratio; size low count = number of patients with values below the cut-off; size high count = no. of patients with values above the
cut-off.
https://doi.org/10.1371/journal.pone.0222259.t004
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cadherin, Glypican-3, PIVKAII, pSMAD2 and TGFBR2 data were analysed, but patients with
evaluable samples were limited (Part A: 30–44 samples and Part B: 12–22 samples). Tumor tis-
sue expression of proteins AFP, TGFBR2, pSMAD2, E-cadherin, PIVKAII, cMET and Glypi-
can-3 was analysed to determine relationship to clinical outcomes in Part A or Part B,
separately or combined. Higher expression of E-cadherin (>median IHC score of 85) was
associated with shorter OS in Part B (n = 20, HR = 3.83, unadjusted p = 0.029), but not in
Parts A and B combined (n = 61, unadjusted p = 0.412). However, when using a higher cut-off
(75% cut point IHC score of 100), higher expression of E-cadherin was associated with a
shorter OS (n = 61, HR = 2.60, unadjusted p = 0.006) in Parts A and B combined. The other
tissue markers did not show an association with survival.
Discussion
In the present study, we observed that median OS was 7.3 months for patients in Part A and
16.8 months for patients in Part B. These survival times were similar to previously reported
results for second-line patients with HCC treated with novel agents [18]. However, in contrast
to previous studies, such as the SHARP trial where no biomarker was established to help with
the dosing of sorafenib in HCC patients, we used a predefined inclusion of patients based on
their serum levels of AFP [19], which is a prognostic covariate in scoring systems such as CLIP
[20]. High baseline levels of plasma TGF-β1 and E-cadherin and low tumor expression of E-
cadherin have also been associated with poor outcome [13, 21].
First, we showed that higher baseline serum AFP and plasma TGF-β1 levels were indeed
associated with shorter OS as previously reported [8, 22]. We also observed that higher plasma
E-cadherin levels at baseline were associated with shorter OS (Fig 1). Next, we showed that
patients who had a response (decrease from baseline >20%) in both AFP and TGF-β1 during
galunisertib therapy had a significantly prolonged OS (median OS 21.5 months). Responses in
plasma TGF-β1 or E-cadherin alone were less significant, with E-cadherin showing the least
effect (Fig 2). Although the downstream effect of TGF-β1 on E-cadherin production and
expression is well reported [23, 24], there are no studies reporting the molecular timing regu-
lating such interactions. Even less investigated is the relationship between TGF-β1 pathway
inhibition and downstream effect on E-cadherin.
There was a greater proportion of TGF-β1 responders among patients with higher baseline
plasma TGF-β1 (73.5%; 50/68) compared to those with lower baseline plasma TGF-β1 (37.8%;
28/74). In contrast, TGF-β1 response was similar in the two baseline AFP cohorts: 50.8% (32/
63) of patients in Part A with higher AFP levels and 59.0% (46/78) of patients in Part B with
lower AFP levels had a TGF-β1 response. Survival was longest in patients with low baseline
TGF-β1 or AFP who experienced a TGF-β1 response during treatment (Fig 3).
Since plasma TGF-β1 levels may serve as a biomarker to assess clinical activity of galuniser-
tib in future randomized trials in a larger HCC population, we assessed the rapidity of the
onset of TGF-β1 response (S1 Fig, Table 2). Responses occurred during the first cycle, with
TGF-β1 response generally occurring first, followed by E-cadherin and AFP responses. The
duration of biomarker response was longest for AFP, perhaps making this marker more reli-
able for when measurements are infrequent. However, plasma TGF-β1 responses may look dif-
ferent if the TGF-β inhibitor were to be given continuously and not intermittently as done for
galunisertib.
The fact that TGF-β1 levels were elevated in a large number of patients suggests that inflam-
mation may have impaired the ability of immune cells to respond to tumor antigens. This was
supported by the data from the larger protein panel (Fig 4, Table 3). IL-6 and IL-8 correlated
with TGF-β1, as did factors associated with liver function and vascular responses.
PLOS ONE Biomarkers and survival with TGF-β1 inhibition in hepatocellular carcinoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0222259 March 25, 2020 12 / 16
Of the eight circulating miRs associated with OS in this study, miR-320a, miR-130b and
miR-18a have previously been detected in plasma or serum of HCC patients [25–27], and
miR-320a, miR-451a, miR-130b and miR-let-7g were previously detected in normal liver and
HCC tumor samples (TCGA data: https://cancergenome.nih.gov/). Thus, several of the top cir-
culating miRs associated with OS may originate from liver or the hepatic tumor. Two miRs,
miR-451a and miR-130b, were previously shown to be prognostic markers in HCC [28, 29];
we also found an association with OS (Table 4).
Finally, tumor tissue analyses were available from a subset of patients. We expected that patients
with high plasma E-cadherin levels would also have low tissue expression of E-cadherin and shorter
survival [30]. However, we observed that patients with high tumor E-cadherin expression had
shorter survival. This assessment was limited by two major facts: (1) the samples originated from
archival specimen and were not taken prior to treatment, and (2) the evaluable sample size was too
small to determine the variability and to make correlations to the plasma levels of E-cadherin.
A possible limitation of our study is the way in which patients were assigned as having
“low” versus “high” levels of the biomarkers TGF-β1 and E-cadherin at baseline, by using the
median of the study population. It would be more ideal to determine “low” versus “high” in
representative groups of healthy volunteers, other disease states, or other cancers.
In conclusion, in a subset of patients with advanced HCC treated with the novel TGF-βRI/
ALK5 inhibitor galunisertib, decreases in circulating AFP and TGF-β1 levels were associated
with longer OS. Future randomized studies will examine the effect of treatment with galuniser-
tib or other TGF-β1 inhibitors in patients with poor prognosis as defined by high baseline lev-
els of AFP or plasma TGF-β1.
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